3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
13
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Endometrial Neoplasms
2
Solid Tumors
1
PIK3CA-Mutated Cancers
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Metastatic Castration-Resistant Prostate Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
HER2-positive Breast Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
Cyclophosphamide
22
blinatumomab
18
Cytarabine
15
fludarabine
13
Azacitidine
12
venetoclax
10
fludarabine phosphate
10
Rituximab
8
Lenalidomide
7
Dexamethasone
7
Methotrexate
6
Daunorubicin
6
Mercaptopurine
5
daratumumab
4
Whole-Body Irradiation
4
Vincristine
4
Melphalan
4
Idarubicin
4
Etoposide
4
Busulfan
4
pembrolizumab
3
obinutuzumab
3
Radiotherapy
3
Maintenance
3
Immunotherapy, Adoptive
3
Imatinib Mesylate
3
Granulocyte Colony-Stimulating Factor
3
Drug Therapy
3
Cladribine
3
Asparaginase
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasm, Residual
×
inavolisib
×
Clear all
NCT05708235
2026-03-05
MiRaDoR
MedSIR
Phase 2
Recruiting
976 enrolled